How Do Peptides Work? Mechanisms Explained

Most peptides exert their effects by binding to G protein-coupled receptors (GPCRs) on the surface of target cells. GPCRs are the largest family of membrane receptors in the human genome, with over 800 members, and they mediate the effects of approximately 30% of all approved drugs. When a peptide binds to its cognate GPCR, it causes a conformational change that activates intracellular G proteins, which in turn trigger second messenger cascades involving cyclic AMP (cAMP), phospholipase C, calcium ions, and other signaling molecules.

The specificity of peptide-receptor interactions explains why peptides can have such targeted effects. Ipamorelin binds selectively to the growth hormone secretagogue receptor (GHS-R1a) without significantly activating other ghrelin-responsive pathways. Semaglutide binds to the GLP-1 receptor with high affinity and also engages cAMP and beta-arrestin pathways in a pattern that differs subtly from native GLP-1, contributing to its distinct pharmacological profile.

Some peptides interact with receptors that are not GPCRs. BPC-157, for instance, has been shown to interact with the FAK-paxillin pathway and the nitric oxide system, which involve tyrosine kinase receptors and intracellular signaling rather than classical GPCR activation. GHK-Cu acts partly through copper-mediated enzymatic effects and partly through modulation of gene expression, affecting over 4,000 genes in genomic studies. The diversity of receptor mechanisms underscores why no single description of how peptides work can capture the full picture.

The glucagon-like peptide-1 (GLP-1) pathway is the best-characterized and most clinically validated peptide signaling system in current medicine. Natural GLP-1 is released by L-cells in the small intestine after meals and acts on GLP-1 receptors in the pancreas, brain, heart, and other tissues.

In the pancreas, GLP-1 receptor activation stimulates insulin secretion from beta cells and suppresses glucagon secretion from alpha cells, but only when blood glucose is elevated (glucose-dependent mechanism). This glucose-dependency is a major safety advantage over older diabetes drugs that could cause hypoglycemia.

In the brain, GLP-1 receptors in the hypothalamus and brainstem regulate appetite and satiety. Activation of these receptors reduces hunger signals and slows gastric emptying, producing the weight loss effects seen with semaglutide and tirzepatide. Emerging research suggests GLP-1 receptor activation in the brain may also affect reward pathways, potentially explaining early data on reduced alcohol and nicotine cravings.

Semaglutide is a synthetic GLP-1 analog with 94% homology to human GLP-1 but engineered with an albumin-binding fatty acid chain and amino acid substitutions that extend its half-life to approximately 7 days. Tirzepatide goes further by acting as a dual GLP-1/GIP agonist, engaging both incretin pathways simultaneously. The newest pipeline candidates, including retatrutide (GLP-1/GIP/glucagon triple agonist) and survodutide (GLP-1/glucagon dual agonist), extend this approach to three-way receptor engagement.

The clinical success of GLP-1 pathway modulation has validated the broader principle that peptide receptor agonism can produce transformative therapeutic outcomes when the target pathway is well-chosen and the molecule is properly engineered.

Growth hormone (GH) release from the anterior pituitary gland is regulated by two opposing peptide signals: growth hormone-releasing hormone (GHRH), which stimulates GH release, and somatostatin, which inhibits it. A third input comes from ghrelin, a peptide produced mainly in the stomach that also stimulates GH release through a separate receptor (GHS-R1a). Peptide growth hormone secretagogues work by mimicking or amplifying one or both of these stimulatory signals.

GHRH analogs include sermorelin (the first 29 amino acids of GHRH), tesamorelin (full-length GHRH with a trans-3-hexenoic acid modification), CJC-1295 (a modified GHRH analog with extended half-life), and Mod GRF 1-29 (modified sermorelin). These peptides bind to the GHRH receptor on pituitary somatotrophs and stimulate GH release through cAMP-dependent pathways. They produce a relatively physiological GH release pattern.

Ghrelin mimetics include ipamorelin, hexarelin, GHRP-2, and GHRP-6. These peptides bind to the GHS-R1a receptor and produce a more robust GH spike. Ipamorelin is notable for its selectivity, producing GH release without significant changes in cortisol, prolactin, or ACTH. GHRP-6 and GHRP-2 are less selective and can increase cortisol and prolactin, as well as stimulate appetite through ghrelin pathway activation.

MK-677 (ibutamoren) is a non-peptide oral GH secretagogue that mimics ghrelin at the GHS-R1a receptor. While not technically a peptide, it is commonly discussed alongside peptide secretagogues due to its identical receptor target.

The most effective GH stimulation protocols in research combine a GHRH analog with a ghrelin mimetic. For example, CJC-1295 plus ipamorelin is one of the most widely referenced combinations because the two peptides act through complementary receptor systems to produce synergistic GH release. The GHRH analog provides the baseline stimulatory signal while the ghrelin mimetic amplifies the pituitary response.

Tissue repair peptides represent a mechanistically diverse category where the specific pathways differ substantially between peptides, even though the end result (accelerated healing) appears similar.

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from human gastric juice that has demonstrated tissue-protective and healing effects across dozens of preclinical studies. Its proposed mechanisms include activation of the FAK-paxillin pathway (involved in cell migration and adhesion), upregulation of growth hormone receptor expression, stimulation of nitric oxide synthesis, promotion of angiogenesis (new blood vessel formation), and modulation of the dopaminergic and serotonergic systems. BPC-157 has shown activity in tendon, ligament, muscle, bone, intestinal, neural, and vascular tissue models. The breadth of its activity has led some researchers to propose it acts as a master regulator of the body's repair processes, though the exact primary mechanism remains debated.

TB-500 is a synthetic fragment of thymosin beta-4 (TB4), a 43-amino-acid peptide found in virtually all human cells. TB-500 promotes tissue repair primarily through upregulation of actin, a protein critical for cell migration and cytoskeletal organization. When tissue is damaged, TB-500 facilitates the migration of endothelial cells and keratinocytes into the wound area. It also reduces inflammation by downregulating pro-inflammatory cytokines and has demonstrated cardiac protective effects in animal models of myocardial infarction.

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide that declines with age. It promotes tissue remodeling through multiple mechanisms: stimulation of collagen and glycosaminoglycan synthesis, attraction of immune cells to injury sites, promotion of nerve outgrowth, and suppression of reactive oxygen species. Genomic studies have shown that GHK-Cu modulates the expression of over 4,000 human genes, resetting the gene expression pattern of damaged tissue toward a profile associated with healthy tissue. It is used both in wound healing research and in cosmetic applications for skin aging.

Neuropeptides are a broad class of signaling molecules that modulate neurotransmission, synaptic plasticity, and neuronal survival. Several peptides under active research target these systems.

Selank is a synthetic analog of the naturally occurring immunopeptide tuftsin, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It modulates GABA-A receptor expression and alters the balance of the monoamine neurotransmitters serotonin, dopamine, and norepinephrine. Clinical studies in Russia have demonstrated anxiolytic effects comparable to benzodiazepines without the sedation, cognitive impairment, or dependence risk. Selank also enhances brain-derived neurotrophic factor (BDNF) expression, which supports neuroplasticity and learning.

Semax is a synthetic analog of adrenocorticotropic hormone (ACTH 4-10) that has been approved in Russia for cognitive impairment and stroke recovery. Its mechanisms include increased BDNF and nerve growth factor (NGF) expression, modulation of dopaminergic and serotonergic systems, and anti-inflammatory effects in neural tissue. Semax has been shown to promote neurite outgrowth and protect neurons from oxidative stress in preclinical models.

Dihexa is a hexapeptide derived from angiotensin IV that has shown remarkable potency in animal models of cognitive function. It acts as a hepatocyte growth factor (HGF) receptor agonist, promoting synaptogenesis (formation of new synaptic connections) at picomolar concentrations. Dihexa is approximately 10 million times more potent than BDNF at promoting synapse formation in vitro, though translating this to human cognitive enhancement requires extensive clinical investigation.

Cerebrolysin is a mixture of low-molecular-weight neuropeptides derived from porcine brain tissue. It contains multiple active peptide fragments that mimic the activity of endogenous neurotrophic factors. Cerebrolysin has the most extensive clinical evidence base among neuropeptides, with randomized controlled trials in Alzheimer's disease, traumatic brain injury, and stroke showing modest but statistically significant improvements in cognitive function.

Several peptides modulate immune function through distinct pathways. These range from direct antimicrobial activity to complex immunoregulatory effects.

LL-37 is the only human cathelicidin antimicrobial peptide. It disrupts bacterial membranes through electrostatic interactions (the positively charged peptide binds to negatively charged bacterial membranes, creating pores that kill the microorganism). Beyond direct antimicrobial activity, LL-37 acts as an immune modulator by recruiting neutrophils and monocytes, promoting wound healing, and modulating the inflammatory response. Dysregulation of LL-37 is associated with conditions including psoriasis (overexpression), chronic wounds (underexpression), and susceptibility to infections.

KPV is a tripeptide (Lys-Pro-Val) derived from alpha-melanocyte stimulating hormone (alpha-MSH). It exerts anti-inflammatory effects by inhibiting NF-kB signaling, one of the master regulatory pathways of the inflammatory response. In preclinical models, KPV has reduced intestinal inflammation (making it of interest for inflammatory bowel disease research) and attenuated skin inflammation.

Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from thymus tissue. It enhances T-cell maturation and function, increases natural killer cell activity, and promotes dendritic cell maturation. Thymosin alpha-1 (marketed as Zadaxin) has been approved in over 30 countries for hepatitis B and C treatment and has been studied as an immune adjuvant in cancer therapy and as an immune modulator in sepsis and COVID-19.

Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide with broad immunomodulatory properties. It suppresses pro-inflammatory cytokine production, promotes regulatory T-cell differentiation, and inhibits Th1 and Th17 immune responses. VIP has been investigated in chronic inflammatory conditions, particularly those with autoimmune components, and has generated interest in mast cell activation syndrome (MCAS) and long COVID protocols.

Several peptides are studied for potential effects on cellular aging and longevity, though this remains among the most speculative areas of peptide research.

Epithalon (Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural peptide epithalamin, produced by the pineal gland. Its proposed mechanism involves activation of telomerase, the enzyme that maintains telomere length. Telomere shortening is one of the hallmarks of cellular aging, and epithalon has been shown to increase telomerase activity in human cell cultures and extend lifespan in rodent studies by approximately 12-24%. Epithalon also stimulates melatonin production from the pineal gland, which declines with age and regulates circadian rhythm and antioxidant defense.

MOTS-c is a mitochondrial-derived peptide encoded by the 12S rRNA gene of mitochondrial DNA. It activates the AMPK pathway, a master regulator of cellular energy metabolism, and promotes glucose uptake and fatty acid oxidation. MOTS-c is sometimes called the exercise mimetic peptide because its effects parallel many metabolic benefits of physical exercise. Levels of MOTS-c decline with age and are lower in individuals with metabolic dysfunction.

SS-31 (elamipretide) targets cardiolipin in the inner mitochondrial membrane, stabilizing the electron transport chain and reducing reactive oxygen species production. Mitochondrial dysfunction is a hallmark of aging, and SS-31 has shown protective effects in models of cardiac ischemia, renal disease, and age-related mitochondrial decline. It has entered clinical trials for Barth syndrome and age-related macular degeneration.

FOXO4-DRI is a peptide that disrupts the interaction between the p53 tumor suppressor and the FOXO4 transcription factor in senescent cells. This interaction normally keeps senescent cells alive; blocking it triggers senescent cell apoptosis (senolysis) while leaving healthy cells unaffected. In aged mice, FOXO4-DRI treatment cleared senescent cells and restored aspects of fitness, fur density, and renal function. This represents a targeted approach to one of the key hallmarks of aging.

Understanding peptide mechanisms provides a critical framework for evaluating the claims made about any peptide, whether in scientific literature, clinical marketing, or online communities.

First, mechanism informs plausibility. If someone claims a peptide treats a particular condition, the first question should be whether the peptide's known mechanism is relevant to that condition's pathophysiology. A GLP-1 receptor agonist producing weight loss is mechanistically logical. A GLP-1 receptor agonist improving tendon repair would require a non-obvious pathway and should be viewed with greater skepticism until supporting evidence is provided.

Second, mechanism predicts side effects. Peptides that activate the ghrelin receptor (like GHRP-6) will likely increase appetite because that is a primary function of the ghrelin system. Peptides that activate GLP-1 receptors will likely cause nausea at initial doses because of their effects on gastric motility. Understanding mechanism helps anticipate and evaluate adverse effect profiles.

Third, mechanism explains stacking rationale. The common combination of CJC-1295 plus ipamorelin is mechanistically logical because they activate two different arms of the GH-releasing system (GHRH receptor and GHS receptor). In contrast, stacking two peptides that both activate the same receptor at maximal doses would be mechanistically redundant and potentially counterproductive through receptor desensitization.

Fourth, mechanism helps assess evidence transferability. Animal study results are more likely to translate to humans when the peptide acts on a receptor system that is conserved across species. The GLP-1 receptor system is highly conserved, which partly explains why GLP-1 agonist results translated well from animal models to human trials. Mechanisms unique to certain species or absent in humans provide weaker translational confidence.

A mechanistic framework does not replace the need for clinical evidence, but it provides a necessary first filter for evaluating the rapidly expanding world of peptide research.